MX2010004623A - Compuestos heterociclicos antiviricos. - Google Patents

Compuestos heterociclicos antiviricos.

Info

Publication number
MX2010004623A
MX2010004623A MX2010004623A MX2010004623A MX2010004623A MX 2010004623 A MX2010004623 A MX 2010004623A MX 2010004623 A MX2010004623 A MX 2010004623A MX 2010004623 A MX2010004623 A MX 2010004623A MX 2010004623 A MX2010004623 A MX 2010004623A
Authority
MX
Mexico
Prior art keywords
antiviral compounds
heterocyclic antiviral
heterocyclic
compounds
hepatitis
Prior art date
Application number
MX2010004623A
Other languages
English (en)
Inventor
Francisco Xavier Talamas
Sharada Shenvi Labadie
Robert James Weikert
Clara Jeou Jen Lin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40521706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010004623(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010004623A publication Critical patent/MX2010004623A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Los compuestos de la fórmula I, en la que Y, R1, R4, A1, A2 y X2 tienen los significados aquí definidos son inhibidores de la polimerasa NS5b del virus de la hepatitis C. Se describen también composiciones y métodos para tratar una infección del HCV y para inhibir la replicación del HCV. (ver fórmula (I)).
MX2010004623A 2008-02-14 2009-02-05 Compuestos heterociclicos antiviricos. MX2010004623A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2862908P 2008-02-14 2008-02-14
US13860308P 2008-12-18 2008-12-18
PCT/EP2009/051306 WO2009101022A1 (en) 2008-02-14 2009-02-05 Heterocyclic antiviral compounds

Publications (1)

Publication Number Publication Date
MX2010004623A true MX2010004623A (es) 2010-06-07

Family

ID=40521706

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004623A MX2010004623A (es) 2008-02-14 2009-02-05 Compuestos heterociclicos antiviricos.

Country Status (18)

Country Link
US (1) US8071797B2 (es)
EP (1) EP2245023B1 (es)
JP (1) JP2011512341A (es)
KR (1) KR20100117073A (es)
CN (1) CN101910145A (es)
AR (1) AR070361A1 (es)
AT (1) ATE539070T1 (es)
AU (1) AU2009214194B2 (es)
BR (1) BRPI0907885A2 (es)
CA (1) CA2714254A1 (es)
CL (1) CL2009000305A1 (es)
ES (1) ES2377280T3 (es)
IL (1) IL204736A0 (es)
MX (1) MX2010004623A (es)
PE (1) PE20091458A1 (es)
RU (1) RU2010137635A (es)
TW (1) TW200936573A (es)
WO (1) WO2009101022A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8293909B2 (en) 2008-09-11 2012-10-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7994171B2 (en) 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8048887B2 (en) * 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2011036128A1 (en) * 2009-09-24 2011-03-31 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
US8324212B2 (en) 2010-02-25 2012-12-04 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8354410B2 (en) 2010-03-11 2013-01-15 Bristol-Meyers Squibb Company Compounds for the treatment of hepatitis C
CN102906080A (zh) * 2010-03-11 2013-01-30 百时美施贵宝公司 治疗丙型肝炎的化合物
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
US8445497B2 (en) 2010-06-30 2013-05-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
SG189985A1 (en) 2010-10-26 2013-06-28 Presidio Pharmaceuticals Inc Inhibitors of hepatitis c virus
US8507683B2 (en) 2010-12-09 2013-08-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2655362A1 (en) 2010-12-22 2013-10-30 Abbvie Inc. Hepatitis c inhibitors and uses thereof
BR112014003556A2 (pt) 2011-08-17 2017-03-21 Glaxosmithkline Llc método de tratamento de vírus, e, composição farmacêutica
CA2844086A1 (en) * 2011-08-19 2013-02-28 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis c virus infections
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
US9303020B2 (en) 2012-02-08 2016-04-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2013148620A1 (en) 2012-03-27 2013-10-03 Bristol-Myers Squibb Company Benzofuran derivatives for the treatment of hepatitis c
WO2014110066A1 (en) 2013-01-10 2014-07-17 Bristol-Myers Squibb Company Macrocyclic benzofuran and azabenzofuran compounds for the treatment of hepatitis c
US8962651B2 (en) 2013-03-13 2015-02-24 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US9738653B2 (en) 2013-03-14 2017-08-22 Bristol-Myers Squibb Company Fused furans for the treatment of hepatitis C
EP3119769A1 (en) * 2014-03-21 2017-01-25 Bristol-Myers Squibb Pharma Company Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis c
ES2688554T3 (es) 2014-03-21 2018-11-05 Bristol-Myers Squibb Company Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis C
EP3119786B1 (en) 2014-03-21 2018-08-01 Bristol-Myers Squibb Company 6h-furo[2,3-e]indole compounds for the treatment of hepatitis c
ES2689278T3 (es) 2014-05-21 2018-11-13 Bristol-Myers Squibb Company Compuestos de 2-(aril o heteroaril)fenilo (aza)benzofurano para el tratamiento de la hepatitis C
US10214534B2 (en) 2014-06-11 2019-02-26 Bristol-Myers Squibb Company Substituted 2-phenyl (AZA)benzofuran compounds for the treatment of hepatitis C
US9957278B2 (en) 2014-08-05 2018-05-01 Bristol-Myers Squibb Company Furopyridine compounds for the treatment of hepatitis C
RU2672257C2 (ru) * 2014-09-26 2018-11-13 Чанчжоу Иньшэн Фармасьютикал Ко., Лтд. Аналог бензофурана в качестве ингибитора ns4b
WO2016054299A1 (en) 2014-10-02 2016-04-07 Bristol-Myers Squibb Company Macrocyclic benzofuran compounds for the treatment of hepatitis c
WO2016133970A1 (en) 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Benzofurans substituted with primary benzamide as hcv inhibitors
WO2016133963A1 (en) 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Benzofurans substituted with secondary benzamide as hcv inhibitors
WO2016133961A1 (en) 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Benzofurans substituted with bicyclic secondary benzamide as hcv inhibitors
WO2016133948A1 (en) 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Benzofuran compounds for the treatment of hepatitis c
US10570108B2 (en) 2015-02-19 2020-02-25 Bristol-Myers Squibb Company Substituted benzofuran compounds for the treatment of hepatitis C
TWI731854B (zh) 2015-03-23 2021-07-01 美商共結晶製藥公司 Ｃ型肝炎病毒聚合酶之抑制劑
CN105732602B (zh) * 2015-09-23 2017-04-19 常州寅盛药业有限公司 作为ns4b抑制剂的苯并呋喃类似物
HUE047785T2 (hu) * 2015-11-19 2020-05-28 Jiangsu Hengrui Medicine Co Benzofurán származék, eljárás annak elõállítására és gyógyszerként történõ alkalmazása
EP3380199A4 (en) 2015-11-24 2019-05-22 L'oreal DEVICE FOR TREATING HAIR

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1731993A (zh) * 2002-11-01 2006-02-08 维洛药品公司 苯并呋喃化合物、组合物以及治疗和预防丙型肝炎病毒感染及相关疾病的方法
CL2007000361A1 (es) * 2006-02-09 2008-01-25 Wyeth Corp Combinacion que comprende un inhibidor de la arn polimerasa del virus de la hepatitis c (vhc) y un inhibidor de la proteasa del vhc; composicion farmaceutica que la comprende; y uso de la combinacion para tratar trastornos asociados con vhc.
CA2676906A1 (en) * 2007-02-12 2008-08-21 Intermune, Inc. Novel inhibitors hepatitis c virus replication

Also Published As

Publication number Publication date
US8071797B2 (en) 2011-12-06
EP2245023A1 (en) 2010-11-03
CL2009000305A1 (es) 2010-02-19
ATE539070T1 (de) 2012-01-15
EP2245023B1 (en) 2011-12-28
AR070361A1 (es) 2010-03-31
BRPI0907885A2 (pt) 2015-07-21
CN101910145A (zh) 2010-12-08
AU2009214194B2 (en) 2012-05-17
IL204736A0 (en) 2010-11-30
TW200936573A (en) 2009-09-01
US20090208449A1 (en) 2009-08-20
PE20091458A1 (es) 2009-09-24
JP2011512341A (ja) 2011-04-21
AU2009214194A1 (en) 2009-08-20
CA2714254A1 (en) 2009-08-20
WO2009101022A1 (en) 2009-08-20
KR20100117073A (ko) 2010-11-02
ES2377280T3 (es) 2012-03-26
RU2010137635A (ru) 2012-03-20

Similar Documents

Publication Publication Date Title
MX2010004623A (es) Compuestos heterociclicos antiviricos.
MX2012003170A (es) Compuestos heterociclicos antivirales.
MX2012008443A (es) Nucleosidos antiviricos.
TW200720285A (en) Nucleoside compounds for treating viral infections
TW200745151A (en) Antiviral nucleosides
MX2009004888A (es) Inhibidores del virus de la hepatitis c.
WO2009069095A3 (en) Antiviral nucleoside compounds
MX2009008872A (es) Compuestos macrociclicos como inhibidores de proteasa ns3 del virus de hepatitis c.
TW200602064A (en) Nucleoside derivatives for treating hepatitis C virus infection
MY157435A (en) Heterocyclic antiviral compounds
TW200724540A (en) Heterocyclic antiviral compounds
MX2009004943A (es) Inhibidores del virus de la hepatitis c.
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
EP2542545A4 (en) INHIBITORS OF HEPATITIS C-VIRUS NS5B POLYMERASE
MX2009004556A (es) Inhibidores de la proteasa ns3 del hcv.
MD4403B1 (ro) Compuşi antivirali în bază de dihidroxiizocromen-naftoimidazoli condensaţi
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
MX2011012541A (es) Compuestos heterociclicos antivirales.
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
MX2012006513A (es) Compuestos heterociclicos antivirales.
MX2011011112A (es) Compuestos antivirales heterociclicos.
MX2011008641A (es) Compuestos heterociclicos antivirales.
WO2012019299A9 (en) Hepatitis c inhibitor compounds
TW200631585A (en) 5-nitro-nucleoside compounds for treating viral infections
MX2011012240A (es) Compuestos heterociclicos antivirales.

Legal Events

Date Code Title Description
FG Grant or registration